Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab

Inclusion Criteria: * age over 20 years * nondiabetic patients requiring cataract surgery or vitrectomy for different posterior segment nonproliferative disorders - controls groups * diabetic patients asking ophthalmologic treatments for different degrees of decreasing of visual acuity - diabetic groups * diabetic patients requiring cataract surgery or vitrectomy - diabetic groups * age related macular degeneration patients asking ophthalmologic treatments for different degrees of decreasing of visual acuity - age related macular degeneration groups * age related macular degeneration patients requiring cataract surgery or vitrectomy - age related macular degeneration groups Exclusion Criteria: * patients under the age of 20 years * patients that did not accept and signed the informed consent of the trial * patients that received any anti-VEGF therapy for any proliferative or inflammatory ocular disease * patients that received any type of intraocular injection with any pharmaceutical agent * patients with any clinical type of malignancy in their pathologic antecedents * patients with recent penetrating trauma (less than 1 year old) * patients operated for different ocular disorders requiring combination with antimetabolites (ex. 5-FU or Mitomycin C with trabeculectomy) * patients with intraocular inflammations or infections or other pathologies that contraindicate open globe surgery or intraocular injections with anti-VEGF blockers